New Regulation to Limit the Sale of Tirzepatide and Dulaglutide
On July 17, 2025, the Province announced that tirzepatide and dulaglutide, more commonly referred to by their brand names Mounjaro and Trulicity, will now be included in the "Limits on Sale" regulation under the Pharmacy Operations and Drug Scheduling Act (PODSA) to preserve supply of these diabetes drugs in British Columbia. This regulation was originally added to PODSA in April 2023 to limit sales of semaglutide to ensure that patients with diabetes in the province have access to these medications.
The College will be responsible for ensuring that all registrants comply with the new regulation. This means that pharmacies and pharmacy professionals must comply with the new regulation in order to ensure that patients in British Columbia have access to the medications they need.
For more information please visit: Province moves to protect supply of two more diabetes drugs (BC Gov News)